Zhou, D.-X.; Wang, X.-H.; Xu, X.; Chen, W.-J.; Wei, J.; Chen, T.-T.; Wei, H.
Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy. Pharmaceutics 2022, 14, 2789.
https://doi.org/10.3390/pharmaceutics14122789
AMA Style
Zhou D-X, Wang X-H, Xu X, Chen W-J, Wei J, Chen T-T, Wei H.
Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy. Pharmaceutics. 2022; 14(12):2789.
https://doi.org/10.3390/pharmaceutics14122789
Chicago/Turabian Style
Zhou, De-Xi, Xiao-He Wang, Xuan Xu, Wen-Jie Chen, Jing Wei, Ting-Tao Chen, and Hong Wei.
2022. "Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy" Pharmaceutics 14, no. 12: 2789.
https://doi.org/10.3390/pharmaceutics14122789
APA Style
Zhou, D. -X., Wang, X. -H., Xu, X., Chen, W. -J., Wei, J., Chen, T. -T., & Wei, H.
(2022). Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice via Combining the Oncolytic Therapy and Immunotherapy. Pharmaceutics, 14(12), 2789.
https://doi.org/10.3390/pharmaceutics14122789